My left shoulder had been a problem for 14 months. Physical therapy twice a week, eccentric loading protocols, even a PRP injection at $900 out of pocket. Range of motion improved maybe 15%. Then I ran 250mcg of BPC-157 subcutaneously, twice daily, for 8 weeks. By week 3, my overhead press was back to pre-injury numbers. By week 6, the clicking was gone. My CRP dropped from 2.1 to 0.8 mg/L across the protocol. I know this is not a clinical trial. I also know my shoulder works again.
I think informed self-experimentation with mechanistically understood, low-toxicity peptides is a rational choice that the evidence-based establishment refuses to take seriously.
The Regulatory Timeline Was Never Built for You
Peter Attia said it best on his recent podcast: "Peptides are a legitimate, powerful class of therapeutics, but the legitimacy is confined to a relatively narrow subset of them." He is right. And the subset he means, the FDA-approved drugs, went through a process designed for pharmaceutical companies with billion-dollar budgets and 10-year horizons. That process exists to protect populations. It was never designed to help a 38-year-old with a torn supraspinatus figure out whether a compound with strong animal data and a known mechanism of action might accelerate healing.
BPC-157 has 3 small human studies on knee pain. They lack control groups. They are not great science. But the animal literature on this compound is enormous: dozens of studies showing tissue repair, angiogenesis, anti-inflammatory action across multiple organ systems. The mechanism, modulation of the nitric oxide system and growth factor expression, is well characterized. This is not some mystery molecule.
Eric Topol called the peptide craze "unfounded." I respect Topol enormously. He is also evaluating the space through a population-health lens where "unfounded" means "no Phase III trial." For someone running their own bloodwork every 6 weeks and tracking HRV daily, the risk calculus looks different. My HRV held steady at 64 through the entire protocol. Liver enzymes, kidney function, CBC: all normal at baseline and at week 8.
Yes, I am a sample size of 1. I label it as such every time.
The Real Danger Is Not the Compound
The Las Vegas incident earlier this year, where 2 women ended up critically ill after peptide injections at an anti-aging festival, is genuinely alarming. The pharmacy board could not even identify what was in the serums. That is not a peptide problem. That is a supply chain problem and a supervision problem. Fining 3 individuals after the fact does nothing to fix the structural issue: gray-market vendors selling vials labeled "research use only" that are clearly packaged for human injection, with zero quality verification.
I source from a U.S. compounding pharmacy that provides certificates of analysis with third-party HPLC testing. I verify the purity data. I dose conservatively based on the animal literature, scaled by body weight. I monitor my own labs. Most people buying peptides online do none of this, and that is where the danger concentrates.
Maya Okafor would say I am overcomplicating things for 95% of people. She is right. I am not writing for 95% of people. I am writing for the person who already has a spreadsheet open.
The fair criticism: we genuinely do not know the long-term effects of exogenous BPC-157 in humans. Tumor promotion is a theoretical risk with any compound that upregulates growth factors. I take that seriously. I limit my protocols to 8 weeks with extended washout periods, and I get imaging annually. The absence of long-term data is a real gap, not a reason to pretend the short-term data does not exist.
The establishment position, wait for the meta-analysis, is comfortable. It is also a position that costs you years of potential benefit on compounds where the downside risk, when sourced and dosed properly, is genuinely low. My shoulder is the proof I needed. Yours might be different. Run the experiment. Track everything. And if the data says stop, stop.
My CRP is still 0.8. I am not waiting for permission to care about that number.
